Parp1-Selective Inhibitor

Use of PARP1-selective and ATR inhibitors to target DDR signalling pathway

Update on PETRA trial investigating a next-generation PARP1 select inhibitor

Targeted cancer therapy: choosing the right assay to assess PARP inhibitors

PARP1 bound by Zejula 360 Spin

Biologic Models

How PARP inhibitors (PARPi) work

(Overview) Beyond PARP1: Ribosylation as a Target for Cancer Therapy

The Society for Translational Oncology

PARP Inhibitors: a Breakthrough in Cancer Therapy?

Coalition for the Life Sciences

The Therapeutic Potential of Novel PARP Inhibitors in the Clinic for Epithelial Ovarian Cancer

SRK-181 as a novel latent TGFβ1 selective inhibitor

Investigating impact of gap scheduling on toxicity of PARP1-selective AZD5305 using bone marrow MPS

AZD9574 - a PARP1 inhibitor for BRCA-mutant tumors - drug annotation

Inside Drug Discovery

Developing novel therapeutic strategies to target DNA damage response

PARP Inhibitors in 2020: Where Are We Now, and Where Are We Going | Webinar | Ambry Genetics

💊 Unlocking Synthetic Lethality: Targeting PARP Inhibition in BRCA1 and BRCA2 Mutant Cancers 🛑

Veliparib misses PFS endpoint, advances to phase III trial

MDedge: news and insights for busy physicians

PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations

What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science Illustrated

Dana-Farber Cancer Institute

Combinations With PARP Inhibitors for Ovarian Cancer

Discovering PARP inhibitor resistance with CRISPR

ACTG Dinner Symposium Highlights | Beyond BRCA testing – does HRD matter? | Prof Michael Friedlander